Effect of 0.3% hydroxypropyl methylcellulose/dextran versus 0.18% sodium hyaluronate in the treatment of ocular surface disease in glaucoma patients: A randomized, double-blind, and controlled study

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 6, 2015, Pages 323-329

  Prabhasawat, Pinnita ^a   Ruangvaravate, Ngamkae ^a   Tesavibul, Nattaporn ^a   Thewthong, Maneerat ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ARTIFICIAL TEAR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DEXTRAN; DRUG PRESERVATIVE; FLUORESCEIN; HYALURONIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; PROSTAGLANDIN DERIVATIVE; PRESERVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORNEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE ASSESSMENT; EYE INFLAMMATION; EYELID; FEMALE; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEIBOMIAN GLAND; OCULAR SURFACE DISEASE; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; STAINING; VISUAL SYSTEM EXAMINATION; DRUG EFFECTS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; DEXTRANS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA; HUMANS; HYALURONIC ACID; HYPROMELLOSE DERIVATIVES; LUBRICANT EYE DROPS; MALE; MEIBOMIAN GLANDS; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84942923561     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0115     Document Type: Article

References (39)

1. The First Visual Impairment Project in Thailand-TVIP, The Fourth National Survey of Blindness, Low Vision and Major Eye Disease in Thailand, 2006-2007.
2. Quigley, H. A., and Broman, A. T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90:262-267, 2006.
3. Sherwood, M. B., Grierson, I., Millar, L., and Hitchings, R. A. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology 96:327-335, 1989.
4. Kuppens, E. V., Stolwijk, T. R., de Keizer, R. J., and van Best, J. A. Basal tear turnover and topical timolol in glaucoma patients and healthy controls by fluorophotometry. Invest. Ophthalmol. Vis. Sci. 33:3442-3448, 1992.
5. Herreras, J. M., Pastor, J. C., Calonge, M., and Asensio, V. M. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 99:1082-1088, 1992.
6. Baudouin, C. Side effects of antiglaucomatous drugs on the ocular surface. Curr. Opin. Ophthalmol. 7:80-86, 1996.
7. Garcia-Feijoo, J., and Sampaolesi, J. R. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin. Ophthalmol. 6:441-446, 2012.
8. Leung, E. W., Medeiros, F. A., and Weinreb, R. N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma 17:350-355, 2008.
9. Inoue, K., Okugawa, K., Kato, S., Inoue, Y., Tomita, G., Oshika, T., et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J. Glaucoma 12:480-485, 2003.
10. Prabhasawat, P., Tesavibul, N., and Kasetsuwan, N. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study. Br. J. Ophthalmol. 91:47-50, 2007.
11. Aragona, P., Papa, V., Micali, A., Santocono, M., and Milazzo, G. Long term treatment with sodium hyaluronatecontaining artificial tears reduces ocular surface damage in patients with dry eye. Br. J. Ophthalmol. 86:181-184, 2002.
12. Gomes, J. A., Amankwah, R., Powell-Richards, A., and Dua, H. S. Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br. J. Ophthalmol. 88:821-825, 2004.
13. Versura, P., Maltarello, M. C., Stecher, F., Caramazza, R., and Laschi, R. Dry eye before and after therapy with hydroxypropyl methylcellulose. Ultrastructural and cytochemical study in 20 patients. Ophthalmologica 198:152-162, 1989.
14. Toda, I., Shinozaki, N., and Tsubota, K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjogren's syndrome. Cornea 15:120-128, 1996.
15. Pauloin, T., Dutot, M., Warnet, J. M., and Rat, P. In vitro modulation of preservative toxicity: high molecular weight hyaluronan decreases apoptosis and oxidative stress induced by benzalkonium chloride. Eur. J. Pharm. Sci. 34:263-273, 2008.
16. Schiffman, R. M., Christianson, M. D., Jacobsen, G., Hirsch, J. D., and Reis, B. L. Reliability and validity of the Ocular Surface Disease Index. Arch. Ophthalmol. 118:615-621, 2000.
17. Prabhasawat, P., Tesavibul, N., and Mahawong, W. A randomized double-masked study of 0. 05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 31:1386-1393, 2012.
18. Lemp, M. A. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 21:221-232, 1995.
19. Baudouin, C. The ocular surface in glucoma. Cornea 28:S14-S19, 2009.
20. Pisella, P. J., Pouliquen, P., and Baudouin, C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 86:418-423, 2002.
21. Chung, S. H., Lee, S. K., Cristol, S. M., Lee, E. S., Lee, D. W., Seo, K. Y., et al. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin. Mol Vis 12:415-421, 2006.
22. Yalvac, I. S., Gedikoglu, G., Karagoz, Y., Akgun, U., Nurozler, A., Koc, F., et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol. Scand. 73:246-248, 1995.
23. Wilson, W. S., Duncan, A. J., and Jay, J. L. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br. J. Ophthalmol. 59:667-669, 1975.
24. De Saint Jean, M., Brignole, F., Bringuier, A. F., Bauchet, A., Feldmann, G., and Baudouin, C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 40:619-630, 1999.
25. Dogan, A. S., Orhan, M., Soylemezoglu, F., Irkec, M., and Bozkurt, B. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin. Experiment. Ophthalmol. 32:62-66, 2004.
26. Cha, S. H., Lee, J. S., Oum, B. S., and Kim, C. D. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin. Experiment. Ophthalmol. 32:180-184, 2004.
27. Baudouin, C., Pisella, P. J., Fillacier, K., Goldschild, M., Becquet, F., De Saint Jean, M., et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 106:556-563, 1999.
28. Baudouin, C., Hamard, P., Liang, H., Creuzot-Garcher, C., Bensoussan, L., and Brignole, F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 111:2186-2192, 2004.
29. Erb, C., Gast, U., and Schremmer, D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch. Clin. Exp. Ophthalmol. 246:1593-1601, 2008.
30. Abelson, M. B., Nally, L., and Ousler, G. W. Dry eye, today and tomorrow. Rev. Ophthalmol. VII:132-134, 2000.
31. Nakamura, M., Hikida, M., Nakano, T., Hamano, T., Kinoshita, S. Characterization of water retentive properties of hyaluronan. Cornea 12:433-436, 1993.
32. Saettone, M. F., Chetoni, P., Torracca, M. T., Burgalassi, S., Giannacini, B. Evaluation of mucoadhesive properties and in vivo activity of opthalmic vehicles based on hyaluronic acid. Int. J. Pharm. 51:203-212, 1989.
33. McCann, L. C., Tomlinson, A., Pearce, E. I., and Papa, V. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea 31:1-5, 2012.
34. Brignole, F., Pisella, P. J., Dupas, B., Baeyens, V., and Baudouin, C. Efficacy and safety of 0. 18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch. Clin. Exp. Ophthalmol. 243:531-538, 2005.
35. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul. Surf. 5:75-92, 2007.
36. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop. Ocul. Surf. 5:163-178, 2007.
37. Monaco, G., Cacioppo, V., Consonni, D., and Troiano, P. Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy. Eur. J. Ophthalmol. 21:243-250, 2011.
38. Konstas, A. G., Voudouragkaki, I. C., Boboridis, K. G., Haidich, A. B., Paschalinou, E., Giannopoulos, T., et al. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv. Ther. 31:592-603, 2014.
39. Phasukkijwatana, N., Lertrit, P., Liammongkolkul, S., and Prabhasawat, P. Stability of epitheliotrophic factors in autologous serum eye drops from chronic Stevens-Johnson syndrome dry eye compared to non-autoimmune dry eye. Curr. Eye Res. 36:775-781, 2011.